<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00306748</url>
  </required_header>
  <id_info>
    <org_study_id>MCP-103-004</org_study_id>
    <nct_id>NCT00306748</nct_id>
  </id_info>
  <brief_title>Phase 2 Study of MD-1100 Acetate Administered for 14 Days to Patients Meeting Criteria for Chronic Constipation</brief_title>
  <official_title>A Randomized, Multicenter, Double-Blind, Parallel-Design, Phase 2 Trial of Oral MD-1100 Acetate Administered for 14 Days Once Daily at 100 ug, 300 ug, 1000 ug, or Placebo to Patients With Chronic Constipation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ironwood Pharmaceuticals, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Ironwood Pharmaceuticals, Inc.</source>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine the safety and gastrointestinal pharmacodynamics
      (stool frequency, stool consistency, stool ease of passage, stool completeness of evacuation)
      of MD-1100 acetate administered daily for 14 days.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>March 2006</start_date>
  <completion_date>August 2006</completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety will be evaluated on an ongoing basis by completing physical examinations, ECGs, clinical laboratory tests, and adverse event reporting.</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>Stool Frequency will be reported daily</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Stool Consistency (Bristol Stool Form Scale) will be reported daily</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Stool Ease of Passage will be reported daily</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Stool Completeness of Evacuation will be reported daily</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient Assessment of Abdominal Discomfort will be reported weekly</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient Assessment of Constipation will be reported weekly</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient Assessment of Overall Relief will be reported weekly</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part 1 of the Irritable Bowel Symptom Severity Scale (IBSSS) will be reported once pre-dose and once post-dose.</measure>
  </secondary_outcome>
  <enrollment>40</enrollment>
  <condition>Constipation</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>MD-1100 Acetate</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male or non-pregnant, non-breastfeeding female, age 18-70 years old at the time of
             first dose;

          -  Sexually active patients of childbearing potential agree to use double-barrier birth
             control;

          -  Females of childbearing potential must complete negative pregnancy tests prior to
             first dose;

          -  Negative colonoscopy within 10 years or completion of negative flexible sigmoidoscopy
             if under the age of 50 provided there is no history of rectal bleeding, weight loss,
             or anemia;

          -  BMI must be greater than/equal to 18.5 and less than 35.0;

          -  Successful completion of physical exam, 12-lead ECG, clinical laboratory tests prior
             to first dose of study medication;

          -  Vital signs must not have clinically-significant findings within 4 hours of first dose
             of study medication;

          -  Patient reports 3 or less spontaneous bowel movements (SBMs) per week and meets 1 or
             more of the following criteria for constipation for 12 weeks in the previous 12
             months: straining at least 25% bowel movements (BMs), lumpy or hard stools at least
             25% of BMs, or sensation of incomplete evacuation at least 25% of BMs;

          -  Patient reports 3 or less SBMs during the 7-day Pre-treatment Period;

          -  Patient is compliant with IVRS for at least 6 days in the 7-day Pre-treatment Period.

        Exclusion Criteria:

          -  Use of investigational drug within 30 days;

          -  Laxative/enema-induced diarrhea within 60 days;

          -  Patient meets ROME II criteria for functional diarrhea;

          -  Most bothersome symptom is moderate or severe abdominal pain or abdominal discomfort;

          -  History of cancer, inflammatory bowel disease, ischemic colitis, bowel resection,
             colostomy, or fecal impaction;

          -  Diagnosis of cathartic colon or laxative/enema abuse, pelvic floor dysfunction,
             evacuation disorder, bulimia, anorexia, or neurological disorders;

          -  Surgery within 30 days or GI surgery within 6 months of first dose of study
             medication. Cholecystectomy and/or appendectomy are acceptable if completed more than
             60 days prior to first dose of study medication;

          -  Patient may not use any disallowed medications (prescription and/or over-the-counter
             treatments for chronic constipation or C-IBS, drugs that target 5-HT4, 5-HT2b, or
             5-HT3 receptors, narcotics, anti-cholinergic agents, GI preparations, etc.) during the
             7-day Pre-treatment Period or during the study. Stable, continuous (30 days or more)
             use of dietary fiber is acceptable.

          -  Any acute or chronic condition that would limit the patient's ability to complete
             and/or participate in the study.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jeffrey M. Johnston, MD, FACP</last_name>
    <role>Study Director</role>
    <affiliation>Microbia, Inc.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Clinical Research Associates</name>
      <address>
        <city>Huntsville</city>
        <state>Alabama</state>
        <zip>35801</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Arkansas Gastroenterology</name>
      <address>
        <city>North Little Rock</city>
        <state>Arkansas</state>
        <zip>72117</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Consultants for Clinical Research of South Florida</name>
      <address>
        <city>Boynton Beach</city>
        <state>Florida</state>
        <zip>33426</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Beth Israel Deaconess Medical Center</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02215</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Chung H. Kim, MD</name>
      <address>
        <city>Pittsford</city>
        <state>New York</state>
        <zip>14534</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UC for Functional GI &amp; Motility Disorders</name>
      <address>
        <city>Chapel Hill</city>
        <state>North Carolina</state>
        <zip>27599-7080</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Vital Research</name>
      <address>
        <city>Greensboro</city>
        <state>North Carolina</state>
        <zip>27408</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sooner Clinical Research</name>
      <address>
        <city>Oklahoma City</city>
        <state>Oklahoma</state>
        <zip>73112</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>ClinSearch</name>
      <address>
        <city>Chattanooga</city>
        <state>Tennessee</state>
        <zip>37304</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Memphis Gastroenterology Clinic</name>
      <address>
        <city>Germantown</city>
        <state>Tennessee</state>
        <zip>38120</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Austin Gastroenterology, P.A.</name>
      <address>
        <city>Austin</city>
        <state>Texas</state>
        <zip>78745</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Trinity Clinic - Corsicana</name>
      <address>
        <city>Corsicana</city>
        <state>Texas</state>
        <zip>75110</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>East Coast Clinical Research, LLC</name>
      <address>
        <city>Virginia Beach</city>
        <state>Virginia</state>
        <zip>23454</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Vantage Clinical Research</name>
      <address>
        <city>Olympia</city>
        <state>Washington</state>
        <zip>98506</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2009</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 20, 2006</study_first_submitted>
  <study_first_submitted_qc>March 23, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 24, 2006</study_first_posted>
  <last_update_submitted>March 22, 2009</last_update_submitted>
  <last_update_submitted_qc>March 22, 2009</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 24, 2009</last_update_posted>
  <keyword>Chronic Constipation</keyword>
  <keyword>Chronic Idiopathic Constipation</keyword>
  <keyword>Constipation</keyword>
  <keyword>CIC</keyword>
  <keyword>CC</keyword>
  <keyword>MD-1100</keyword>
  <keyword>MD-1100 Acetate</keyword>
  <keyword>Microbia</keyword>
  <keyword>Microbia, Inc.</keyword>
  <keyword>linaclotide</keyword>
  <keyword>linaclotide acetate</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Constipation</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

